.
08 abril 2020
FDA Grants Nivolumab/Ipilimumab Plus Chemo Priority Review in Frontline NON SMALL CELL LUNG Cáncer ( NSCLC ). The FDA is scheduled to decide on the application by August 6, 2020.
Entrada más reciente
Entrada antigua
Inicio